Search

Subject Neoadjuvant chemotherapy -- Survival -- Advanced age

1. Neoadjuvant therapy in elderly patients receiving FOLFIRINOX or gemcitabine/nab-paclitaxel for borderline resectable or locally advanced pancreatic cancer is feasible and lead to a similar oncological outcome compared to non-aged patients – Results of the RESPECT-Study. (December 2020)

Authors:
Weniger, Maximilian; Moir, John; Damm, Marko; Maggino, Laura; Kordes, Maximilian; Rosendahl, Jonas; Ceyhan, Güralp O.; Schorn, Stephan; Schmid, Daniel; D'Haese, Jan G.; Böck, Stephan; Kruger, Stephan; Haas, Michael; Röder, Falk; Chiaro, Marco del; Löhr, Matthias; Tamburrino, Domenico; Masini, Gai...
Journal:
Surgical oncology
Issue:
Volume 35(2020)
Page Start:
285
Record Type:
Journal Article
View Content:
Available online (eLD content is only available in our Reading Rooms) ↗

Limit your search

  • Neoadjuvant chemotherapy -- Survival -- Advanced age 1